<DOC>
	<DOC>NCT01034969</DOC>
	<brief_summary>The Firazyr® Patient Registry is a prospective, observational study designed to document the routine clinical outcomes over time in patients treated with Firazyr® in countries where it is currently approved. The data collected will be used to evaluate the safety of Firazyr® in routine clinical practice and as a data source for post-marketing investigations.</brief_summary>
	<brief_title>Firazyr® Patient Registry Protocol (Icatibant Outcome Survey - IOS)</brief_title>
	<detailed_description>The Firazyr® Patient Registry is a multicenter, prospective, observational study for patients treated with Firazyr® in countries where it is currently approved. The entry of patients into the Firazyr® Registry is at the discretion of the physician and the patient and is not a pre-requisite for prescribing Firazyr®.</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<mesh_term>Icatibant</mesh_term>
	<criteria>Each patient must meet all of the following criteria to be enrolled in this registry. 1. Diagnosis of at least 1 of the following: HAE type I or II HAE with normal C1 inhibitor ACE I induced angioedema Non histaminergic idiopathic angioedema Acquired angioedema 2. Signed and dated written informed consent from the patient or, for patients aged &lt;18 years (or as per local regulation, such as &lt;16 years in the United Kingdom [UK]), parent and/or patient's legally authorized representative (LAR), and assent of the minor where applicable 3. At sites only participating in the drug registry aspect of this study, patients must have taken at least 1 dose of Firazyr (icatibant). 1. Patients enrolled in clinical trials where the product is blinded or where the product under investigation is for the treatment of HAE, ACE I induced angioedema, non histaminergic idiopathic angioedema, or acquired angioedema. 2. Patients enrolled in another Shiresponsored registry involving products for the treatment of HAE, ACE I induced angioedema, non histaminergic idiopathic angioedema, or acquired angioedema.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hereditary angioedema</keyword>
</DOC>